Searchable abstracts of presentations at key conferences in endocrinology

ea0029p584 | Diabetes | ICEECE2012

Decreased sucrose preference in humans and rodents with diabetes

Yu J , Kim M

Objective: Craving of sweet foods and sucrose may be a big obstacle for glycemic control of diabetic patients. It is generally believed that diabetic patients may prefer sweet taste. However, few studies have examined sucrose preference in diabetic patients. Therefore, we investigated changes in sucrose preference in diabetic condition.Research design and methods: We performed two-alternative staircase methods and forced-choice tracking procedures to ass...

ea0011p672 | Reproduction | ECE2006

Bone mass density in 180 women with premature ovarian failure

Vujovic S , Stojanovic M , Penezic Z , Ivovic M , Kovacevic M , Barac B , Marina Lj , Drezgic M

Premature ovarian failure (POF) is characterized by amenorrhea, hypergonadotropism and hypoestrogensm in women under 40 years. Sex steroids play an important role in maintaining bone mass and cessation of ovarian function results in significant bone loss.Objective: To evaluate bone mass density (BMD) and factors influencing it in women with POF.Design & methods: First group of 144 women with spontaneous POF (I), 39.7±7.6 y...

ea0026p4 | Adrenal cortex | ECE2011

Effects and kinetics of mitotane in in vitro and in vivo models of adrenocortical carcinoma

Luconi M , Poli G , Mangoni M , Pezzati P , Francalanci M , Gelmini S , Canu L , Cantini G , Serio M , Mannelli M

Adrenocortical carcinoma (ACC) is a rare aggressive tumor with a poor prognosis. At present, early diagnosis followed by total surgical tumor resection is the only valuable option for ACC cure and mitotane (MTT) is the only specific drug available for pharmacological treatment. However, its effects seem to be mainly due to its adrenocortical cytotoxicity and its bioavailability and cellular mechanism of action are still unknown, making it difficult to develop less toxic multid...

ea0003oc10 | Endocrine Neoplasia | BES2002

2-methoxyestradiol sulphamatas induce G2-M arrest and apoptosis in ER-VE MDA-MB-231 breast cancer cells

Malini B , Purohit A , Leese M , Potter B , Reed M

2-Methoxyoestrogens are emerging as a new class of anti-neoplastic agents. 2-Methoxyoestradiol (2-MeOE2), an endogenous oestrogen metabolite, has shown anti-proliferative effects in ER+ve and ER-ve breast cancer cell lines. In this study we have investigated the effects of sulphamoylated derivatives of 2-MeOE2, 2-methoxyoestradiol-3-O-monosulphamate (2-MeOE2MATE) and 2-methoxyoestradiol 3,17 bis sulphamate (2-MeOE2bisMATE) in ER-ve MDA-MB-231 cells. Both 2-MeOE2MATE and 2-MeOE...

ea0026p326 | Obesity | ECE2011

Serum leptin level and its association with body composition in obese children

Vishnevskaya M , Solnceva A

Body composition using dual energy X-ray absorptiometry (DEXA) can be used as an specific method for measuring fat mass and identify individual risk for cardiovascular and metabolic complications in obese children.Objective: To investigate serum leptin level and its relationship with fat distribution in obese children.Materials and methods: Eighty-seven children (male/female=43/44, mean age 12.81±0.5 years). obese (BMI>95 ...

ea0026p486 | Thyroid cancer | ECE2011

mTOR inhibition hampers cell viability in selected human medullary thyroid carcinoma primary cultures

Filieri C , Zatelli M C , Minoia M , Tagliati F , Buratto M , Ambrosio M R , Pelizzo M , degli Uberti E C

It has been demonstrated that everolimus, an mTOR inhibitor, has potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures. We aimed at evaluating the possible antiproliferative effects of everolimus in a group of 20 human MTC in primary culture. To this purpose, 20 MTCs were dispersed in primary cultures, treated without or with 1 nM – 1 μM everolimus, 10 nM SOM230, and/or 50 nM IGF1. Cell viab...

ea0029oc1.1 | Pituitary Clinical I | ICEECE2012

Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study

Colao A. , Bronstein M. , Freda P. , Gu F. , Shen C. , Gadelha M. , Fleseriu M. , Hermosillo Resendiz K. , Ruffin M. , Chen Y. , Sheppard M.

Introduction: Using the criterion of GH<2.5 μg/l and normalized IGF1, response rates to currently available somatostatin analogues in medically-naïve patients with acromegaly are 20–25% after 12 m. The broader somatostatin receptor binding profile of pasireotide may potentially improve response rates. This randomized, double-blind 12-m study compared pasireotide LAR with octreotide LAR.Methods: Patients with acromegaly (GH>5 μ...

ea0041nsa2 | (1) | ECE2016

Engineering an ovary bioprosthesis

Laronda Monica M

Patients with gonadotoxicity due to disease treatment, or who face primary gonadal insufficiency as a result of genetic causes, have limited options for long-term endocrine and fertility support. Current fertility options, such as egg or embryo banking, exclude women with hormone-responsive cancers and pre-pubertal children. This highlights the urgency of addressing this currently unmet need with innovative engineering solutions. Our objective is to create an ovary bioprosthes...

ea0031pl1biog | Society for Endocrinology Dale Medal Lecture | SFEBES2013

Society for Endocrinology Dale Medal Lecture

Evans Ronald M

Dr. Ronald M Evans is known for his discoveries and characterization of nuclear hormone receptors, the establishment of the nuclear receptor super family and the elucidation of their universal mechanism of action, this revealed how receptor activation by lipophilic hormones and drugs are transformed into physiology and the treatment of disease.Dr R M Evans obtained his BA and PhD from the University of California, Los Angeles, School of Medicine in 1970 ...

ea0053p07 | (1) | OU2018

The use of ketogenic diet in a patient with post-prandial hyperinsulinemic hypoglycaemia after m Roux-en-Y Gastric Bypass surgery: a case study

Abbott Sally , Dindol Naomi , Singhal Rishi , Helmy Ahmed , Ahmed Mohamed , Bellary Sri , Tahrani Abd

Background: Hyperinsulinemic hypoglycaemia (HH) after Roux-en-Y gastric bypass (RYGB) is rare. Patients typically present with post-prandial hypoglycaemia >1 year after surgery and once weight loss has plateaued. Despite multiple treatment options, the management of these patients remains challenging.Clinical case: A 31-year-old female was referred for bariatric surgery with a BMI of 41.4 kg/m2. In the year preceding the r...